Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in t...
Jun 30, 2025, 3:15 PM EDT - 6 days ago
Jun 23, 2025, 8:00 AM EDT - 14 days ago
Feb 4, 2025, 9:25 AM EST - 5 months ago
Jan 30, 2025, 8:00 AM EST - 5 months ago
Dec 4, 2024, 4:56 PM EST - 7 months ago
Dec 2, 2024, 7:00 PM EST - 7 months ago
Aug 16, 2022, 5:48 PM EDT - 3 years ago